TOLLIP SNP and Antimicrobial Treatment Effect in Idiopathic Pulmonary Fibrosis.,American Journal of Respiratory and Critical Care Medicine

当前位置： X-MOL 学术 › Am. J. Respir. Crit. Care Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

TOLLIP SNP and Antimicrobial Treatment Effect in Idiopathic Pulmonary Fibrosis.
American Journal of Respiratory and Critical Care Medicine ( IF 19.3 ) Pub Date : 2024-08-15 , DOI: 10.1164/rccm.202312-2224le
William Whalen ₁ , Kristin Berger ₁ , John S Kim ₂ , Will Simmons ₃ , Shwu-Fan Ma ₂ , Robert J Kaner _{1,

4} , Fernando J Martinez ₁ , Kevin J Anstrom ₅ , Helen Parfrey ₆ , Toby M Maher _{7,

8} , Matthew Hammond ₉ , Allan B Clark ₉ , David Thickett ₁₀ , R Gisli Jenkins ₈ , Andrew M Wilson ₁₁ , Imre Noth ₂

Affiliation

Division of Pulmonary and Critical Care, Department of Medicine.
Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia.
Division of Biostatistics, Department of Population Health Sciences, and.
Department of Genetic Medicine, New York Presbyterian-Weill Cornell Medicine, New York, New York.
University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, North Carolina.
University of Cambridge and Royal Papworth Hospital National Health Service Foundation Trust, Cambridge, United Kingdom.
University of Southern California, Los Angeles, California.
National Heart and Lung Institute, Imperial Biomedical Research Centre, and National Institute for Health and Care Research Margaret Turner Warwick Centre for Fibrosing Lung Disease, Imperial College London, London, United Kingdom.
Norwich Clinical Trials Unit and.
Institute of Inflammation and Aging, University of Birmingham, Birmingham, United Kingdom.
Norwich Medical School, University of East Anglia, Norwich, United Kingdom; and.

中文翻译：

TOLLIP SNP 和特发性肺纤维化的抗菌治疗效果。

更新日期：2024-08-15

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南